Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides : an in vitro model for treatment
Identifieur interne : 000109 ( PascalFrancis/Checkpoint ); précédent : 000108; suivant : 000110Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides : an in vitro model for treatment
Auteurs : J. Lisziewicz [États-Unis] ; D. Sun [États-Unis] ; M. Klotman [États-Unis] ; S. Agrawal ; P. Zamecnik ; R. Gallo [États-Unis]Source :
- Proceedings of the National Academy of Sciences of the United States of America [ 0027-8424 ] ; 1992.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
We have developed a culture system, simulating in vivo conditions of human immunodeficiency virus type 1 (HIV-1) injection, to evaluate the long-term efficacy of antisense oligonucleotide treatment. Five oligonucleotide phosphorothioates (28-mers), complementary to different regions of HIV-1 RNA, blocked replication of the virus in a sequence-specific manner at 1 μM concentration. Variations in antiviral activity were seen among the different oligonucleotides, invealing an effect of target selection
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:93-0236257Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides : an in vitro model for treatment</title><author><name sortKey="Lisziewicz, J" sort="Lisziewicz, J" uniqKey="Lisziewicz J" first="J." last="Lisziewicz">J. Lisziewicz</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>NIH, national cancer inst., lab. tumor cell biology</s1><s2>Bethesda MD 20892</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Bethesda MD 20892</wicri:noRegion></affiliation></author><author><name sortKey="Sun, D" sort="Sun, D" uniqKey="Sun D" first="D." last="Sun">D. Sun</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>NIH, national cancer inst., lab. tumor cell biology</s1><s2>Bethesda MD 20892</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Bethesda MD 20892</wicri:noRegion></affiliation></author><author><name sortKey="Klotman, M" sort="Klotman, M" uniqKey="Klotman M" first="M." last="Klotman">M. Klotman</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>NIH, national cancer inst., lab. tumor cell biology</s1><s2>Bethesda MD 20892</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Bethesda MD 20892</wicri:noRegion></affiliation></author><author><name sortKey="Agrawal, S" sort="Agrawal, S" uniqKey="Agrawal S" first="S." last="Agrawal">S. Agrawal</name></author><author><name sortKey="Zamecnik, P" sort="Zamecnik, P" uniqKey="Zamecnik P" first="P." last="Zamecnik">P. Zamecnik</name></author><author><name sortKey="Gallo, R" sort="Gallo, R" uniqKey="Gallo R" first="R." last="Gallo">R. Gallo</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>NIH, national cancer inst., lab. tumor cell biology</s1><s2>Bethesda MD 20892</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Bethesda MD 20892</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">93-0236257</idno><date when="1992">1992</date><idno type="stanalyst">PASCAL 93-0236257 INIST</idno><idno type="RBID">Pascal:93-0236257</idno><idno type="wicri:Area/PascalFrancis/Corpus">000109</idno><idno type="wicri:Area/PascalFrancis/Curation">000105</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000109</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000109</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides : an in vitro model for treatment</title><author><name sortKey="Lisziewicz, J" sort="Lisziewicz, J" uniqKey="Lisziewicz J" first="J." last="Lisziewicz">J. Lisziewicz</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>NIH, national cancer inst., lab. tumor cell biology</s1><s2>Bethesda MD 20892</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Bethesda MD 20892</wicri:noRegion></affiliation></author><author><name sortKey="Sun, D" sort="Sun, D" uniqKey="Sun D" first="D." last="Sun">D. Sun</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>NIH, national cancer inst., lab. tumor cell biology</s1><s2>Bethesda MD 20892</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Bethesda MD 20892</wicri:noRegion></affiliation></author><author><name sortKey="Klotman, M" sort="Klotman, M" uniqKey="Klotman M" first="M." last="Klotman">M. Klotman</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>NIH, national cancer inst., lab. tumor cell biology</s1><s2>Bethesda MD 20892</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Bethesda MD 20892</wicri:noRegion></affiliation></author><author><name sortKey="Agrawal, S" sort="Agrawal, S" uniqKey="Agrawal S" first="S." last="Agrawal">S. Agrawal</name></author><author><name sortKey="Zamecnik, P" sort="Zamecnik, P" uniqKey="Zamecnik P" first="P." last="Zamecnik">P. Zamecnik</name></author><author><name sortKey="Gallo, R" sort="Gallo, R" uniqKey="Gallo R" first="R." last="Gallo">R. Gallo</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>NIH, national cancer inst., lab. tumor cell biology</s1><s2>Bethesda MD 20892</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Bethesda MD 20892</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Proceedings of the National Academy of Sciences of the United States of America</title><title level="j" type="abbreviated">Proc. Natl. Acad. Sci. U. S. A.</title><idno type="ISSN">0027-8424</idno><imprint><date when="1992">1992</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Proceedings of the National Academy of Sciences of the United States of America</title><title level="j" type="abbreviated">Proc. Natl. Acad. Sci. U. S. A.</title><idno type="ISSN">0027-8424</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>AIDS</term><term>Antisense DNA</term><term>Antiviral</term><term>Chemical synthesis</term><term>Chemotherapy</term><term>HIV-1 virus</term><term>In vitro</term><term>In vitro replication</term><term>Infection</term><term>Inhibition</term><term>Mechanism of action</term><term>Models</term><term>Nucleotide sequence</term><term>Specificity</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Virus HIV1</term><term>Antiviral</term><term>Inhibition</term><term>Infection</term><term>Modèle</term><term>Replication in vitro</term><term>Immunodéficit acquis syndrome</term><term>Spécificité</term><term>Séquence nucléotide</term><term>Chimiothérapie</term><term>Traitement</term><term>In vitro</term><term>Synthèse chimique</term><term>Mécanisme action</term><term>Lignée MOLT3</term><term>DNA antisens</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We have developed a culture system, simulating in vivo conditions of human immunodeficiency virus type 1 (HIV-1) injection, to evaluate the long-term efficacy of antisense oligonucleotide treatment. Five oligonucleotide phosphorothioates (28-mers), complementary to different regions of HIV-1 RNA, blocked replication of the virus in a sequence-specific manner at 1 μM concentration. Variations in antiviral activity were seen among the different oligonucleotides, invealing an effect of target selection</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0027-8424</s0></fA01><fA02 i1="01"><s0>PNASA6</s0></fA02><fA03 i2="1"><s0>Proc. Natl. Acad. Sci. U. S. A.</s0></fA03><fA05><s2>89</s2></fA05><fA06><s2>23</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides : an in vitro model for treatment</s1></fA08><fA11 i1="01" i2="1"><s1>LISZIEWICZ (J.)</s1></fA11><fA11 i1="02" i2="1"><s1>SUN (D.)</s1></fA11><fA11 i1="03" i2="1"><s1>KLOTMAN (M.)</s1></fA11><fA11 i1="04" i2="1"><s1>AGRAWAL (S.)</s1></fA11><fA11 i1="05" i2="1"><s1>ZAMECNIK (P.)</s1></fA11><fA11 i1="06" i2="1"><s1>GALLO (R.)</s1></fA11><fA14 i1="01"><s1>NIH, national cancer inst., lab. tumor cell biology</s1><s2>Bethesda MD 20892</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></fA14><fA20><s1>11209-11213</s1></fA20><fA21><s1>1992</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>574</s2><s5>354000032371390230</s5></fA43><fA44><s0>0000</s0></fA44><fA45><s0>25 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>93-0236257</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i2="1"><s0>Proceedings of the National Academy of Sciences of the United States of America</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>We have developed a culture system, simulating in vivo conditions of human immunodeficiency virus type 1 (HIV-1) injection, to evaluate the long-term efficacy of antisense oligonucleotide treatment. Five oligonucleotide phosphorothioates (28-mers), complementary to different regions of HIV-1 RNA, blocked replication of the virus in a sequence-specific manner at 1 μM concentration. Variations in antiviral activity were seen among the different oligonucleotides, invealing an effect of target selection</s0></fC01><fC02 i1="01" i2="X"><s0>002B02S05</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Virus HIV1</s0><s2>NW</s2></fC03><fC03 i1="01" i2="X" l="ENG"><s0>HIV-1 virus</s0><s2>NW</s2></fC03><fC03 i1="01" i2="X" l="SPA"><s0>HIV-1 virus</s0><s2>NW</s2></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Antiviral</s0></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Antiviral</s0></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Antiviral</s0></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Inhibition</s0></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Inhibition</s0></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Inhibición</s0></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Infection</s0></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Infection</s0></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Infección</s0></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Modèle</s0></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Models</s0></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Modelo</s0></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Replication in vitro</s0></fC03><fC03 i1="06" i2="X" l="ENG"><s0>In vitro replication</s0></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Replicación in vitro</s0></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Immunodéficit acquis syndrome</s0><s2>NM</s2></fC03><fC03 i1="07" i2="X" l="ENG"><s0>AIDS</s0><s2>NM</s2></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Inmunodeficiencia adquirida síndrome</s0><s2>NM</s2></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Spécificité</s0></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Specificity</s0></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Especificidad</s0></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Séquence nucléotide</s0></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Nucleotide sequence</s0></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Secuencia nucleótido</s0></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Chimiothérapie</s0></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Chemotherapy</s0></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Quimioterapia</s0></fC03><fC03 i1="11" i2="X" l="FRE"><s0>Traitement</s0></fC03><fC03 i1="11" i2="X" l="ENG"><s0>Treatment</s0></fC03><fC03 i1="11" i2="X" l="GER"><s0>Aufbereiten</s0></fC03><fC03 i1="11" i2="X" l="SPA"><s0>Tratamiento</s0></fC03><fC03 i1="12" i2="X" l="FRE"><s0>In vitro</s0></fC03><fC03 i1="12" i2="X" l="ENG"><s0>In vitro</s0></fC03><fC03 i1="12" i2="X" l="SPA"><s0>In vitro</s0></fC03><fC03 i1="13" i2="X" l="FRE"><s0>Synthèse chimique</s0></fC03><fC03 i1="13" i2="X" l="ENG"><s0>Chemical synthesis</s0></fC03><fC03 i1="13" i2="X" l="GER"><s0>Chemische Synthese</s0></fC03><fC03 i1="13" i2="X" l="SPA"><s0>Síntesis química</s0></fC03><fC03 i1="14" i2="X" l="FRE"><s0>Mécanisme action</s0></fC03><fC03 i1="14" i2="X" l="ENG"><s0>Mechanism of action</s0></fC03><fC03 i1="14" i2="X" l="SPA"><s0>Mecanismo acción</s0></fC03><fC03 i1="15" i2="X" l="FRE"><s0>Lignée MOLT3</s0><s4>INC</s4></fC03><fC03 i1="16" i2="X" l="FRE"><s0>DNA antisens</s0><s4>CD</s4></fC03><fC03 i1="16" i2="X" l="ENG"><s0>Antisense DNA</s0><s4>CD</s4></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Virus immunodéficience humaine</s0><s2>NW</s2></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Human immunodeficiency virus</s0><s2>NW</s2></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Human immunodeficiency virus</s0><s2>NW</s2></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Lentivirinae</s0><s2>NW</s2></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Lentivirinae</s0><s2>NW</s2></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Lentivirinae</s0><s2>NW</s2></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Retroviridae</s0><s2>NW</s2></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Retroviridae</s0><s2>NW</s2></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Retroviridae</s0><s2>NW</s2></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Virose</s0></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Viral disease</s0></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Virosis</s0></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Immunopathologie</s0></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Immunopathology</s0></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Inmunopatología</s0></fC07><fC07 i1="07" i2="X" l="FRE"><s0>Hémopathie</s0></fC07><fC07 i1="07" i2="X" l="ENG"><s0>Hemopathy</s0></fC07><fC07 i1="07" i2="X" l="SPA"><s0>Hemopatía</s0></fC07><fN21><s1>076</s1></fN21></pA></standard></inist><affiliations><list><country><li>États-Unis</li></country></list><tree><noCountry><name sortKey="Agrawal, S" sort="Agrawal, S" uniqKey="Agrawal S" first="S." last="Agrawal">S. Agrawal</name><name sortKey="Zamecnik, P" sort="Zamecnik, P" uniqKey="Zamecnik P" first="P." last="Zamecnik">P. Zamecnik</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Lisziewicz, J" sort="Lisziewicz, J" uniqKey="Lisziewicz J" first="J." last="Lisziewicz">J. Lisziewicz</name></noRegion><name sortKey="Gallo, R" sort="Gallo, R" uniqKey="Gallo R" first="R." last="Gallo">R. Gallo</name><name sortKey="Klotman, M" sort="Klotman, M" uniqKey="Klotman M" first="M." last="Klotman">M. Klotman</name><name sortKey="Sun, D" sort="Sun, D" uniqKey="Sun D" first="D." last="Sun">D. Sun</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000109 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000109 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:93-0236257
|texte= Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides : an in vitro model for treatment
}}
| This area was generated with Dilib version V0.6.33. |  |